{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:45:58Z","timestamp":1787309158243,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015250","name":"NIHR Bristol Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102503","type":"journal-article","created":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T10:34:58Z","timestamp":1600598098000},"page":"102503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Evaluation of the impact of intrathecal baclofen on the walking ability of people with Multiple Sclerosis related spasticity."],"prefix":"10.1016","volume":"46","author":[{"given":"Y.","family":"Sammaraiee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.L.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-3382","authenticated-orcid":false,"given":"R.A.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2020.102503_bib0007","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1191\/1352458506ms1232sr","article-title":"Intrathecal baclofen for treatment of spasticity of multiple sclerosis subjects","volume":"12","author":"Ben","year":"2006","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.msard.2020.102503_bib0008","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1017\/S031716710003986X","article-title":"Long-term intrathecal baclofen therapy in subjects with intractable spasticity","volume":"22","author":"Becker","year":"1995","journal-title":"Can J Neurol Sci"},{"issue":"9313","key":"10.1016\/j.msard.2020.102503_bib0001","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.msard.2020.102503_bib0017","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1177\/1352458510395056","article-title":"Intrathecal baclofen in multiple sclerosis: too little, too late?","volume":"17","author":"Erwin","year":"2011","journal-title":"Mult Scler"},{"issue":"6 Suppl","key":"10.1016\/j.msard.2020.102503_bib0005","first-page":"3","article-title":"Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry","volume":"5","author":"Fox","year":"2015","journal-title":"Neurodegener Dis Manag"},{"issue":"10127","key":"10.1016\/j.msard.2020.102503_bib0004","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.msard.2020.102503_bib0006","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7224\/1537-2073.2012-053","article-title":"Natural history of multiple sclerosis symptoms","volume":"15","author":"Kister","year":"2013","journal-title":"Int J MS Care"},{"issue":"11","key":"10.1016\/j.msard.2020.102503_bib0016","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102503_bib0014","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3171\/2017.5.JNS162925","article-title":"Early outcomes after intrathecal baclofen therapy in ambulatory subjects with multiple sclerosis","volume":"129","author":"Lee","year":"2018","journal-title":"J Neurosurg"},{"key":"10.1016\/j.msard.2020.102503_bib0009","doi-asserted-by":"crossref","unstructured":"McCormick ZL, Chu SK, Binler D et\u00a0al. Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life. PMR2016;8(6):553-562.","DOI":"10.1016\/j.pmrj.2015.10.005"},{"issue":"2","key":"10.1016\/j.msard.2020.102503_bib0002","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler"},{"issue":"17","key":"10.1016\/j.msard.2020.102503_bib0003","first-page":"1694","article-title":"Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.msard.2020.102503_bib0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1046\/j.1525-1403.1999.00108.x","article-title":"Intrathecal baclofen therapy for spinal origin spasticity: spinal cord injury, spinal cord disease, and multiple sclerosis","volume":"2","author":"Ochs","year":"1999","journal-title":"Neuromodulation"},{"issue":"6","key":"10.1016\/j.msard.2020.102503_bib0011","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2340\/16501977-0811","article-title":"Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up","volume":"43","author":"Rekand","year":"2011","journal-title":"J Rehabil Med"},{"key":"10.1016\/j.msard.2020.102503_bib0015","doi-asserted-by":"crossref","unstructured":"R. Farrell, M. Summers, E. Keenan, K. Buchanan, H. Lee, H. Padillo, V. Stevenson. Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in subjects with intractable MS related spasticity. Poster presented at: ECTRIMS; 2018 Oct 10; Berlin.","DOI":"10.26226\/morressier.5b719e475aff74008ae4cac5"},{"key":"10.1016\/j.msard.2020.102503_bib0012","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.msard.2018.10.009","article-title":"Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience","volume":"27","author":"Sammaraiee","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.msard.2020.102503_bib0013","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-005-0060-4","article-title":"Long-term intrathecal baclofen therapy in ambulatory subjects with spasticity","volume":"253","author":"Sadiq","year":"2006","journal-title":"J Neurol"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:58:12Z","timestamp":1761901092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":17,"alternative-id":["S2211034820305782"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102503","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the impact of intrathecal baclofen on the walking ability of people with Multiple Sclerosis related spasticity.","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102503"}}